November 7th 2024
Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.
September 4th 2024
March 29th 2024
Matthew Powell, MD, presents findings from a second interim analysis of part 1 from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial investigating the combination of dostarlimab-gxly plus carboplatin/paclitaxel compared with placebo/chemotherapy in patients with primary advanced or recurrent endometrial cancer.
August 10th 2023
The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.
An overview of ongoing research in the endometrial cancer treatment space.
August 3rd 2023
The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.
A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.
July 27th 2023
Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.
The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.
July 20th 2023
Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.
A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.
July 13th 2023
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.
July 6th 2023
A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.
An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.
June 29th 2023
Matthew Powell, MD, presents data from the blinded independent central review of the RUBY trial, which studied dostarlimab in patients with primary advanced or recurrent endometrial cancer.
Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.
A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.
October 23rd 2018
Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses tumor mutational burden (TMB) in ovarian cancer.
October 5th 2018
Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses the future of immunotherapy in ovarian cancer.